Flurofen

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Flurofen

Property Description
Active Ingredient Flurbiprofen
Form Ophthalmic Solution (Eye Drops)
Pharmacological Class Non-Steroidal Anti-Inflammatory Drug (NSAID)
General Purpose Reduction of Inflammation and Pain
Origin Synthetic

Flurofen Defined: A Propionic Acid NSAID

The medicinal preparation known as Flurofen contains Flurbiprofen as its core active ingredient, which is classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). Flurbiprofen is a synthetic compound that belongs specifically to the propionic acid derivative subclass, a family of medicines clinically recognized for their powerful anti-inflammatory capabilities. The drug’s fundamental identity is rooted in its established role as an agent for mitigating inflammatory and associated pain responses, differentiating it from systemic steroids or antimicrobials.

Form and Composition: The Topical Ophthalmic Solution

Flurofen is typically formulated as a sterile Ophthalmic Solution, a single-ingredient product intended for direct application to the eye surface via the Topical Ocular route. The preparation consists of Flurbiprofen dissolved within an aqueous solution vehicle. This specific liquid formulation is a distinctive feature, enabling the drug to be delivered in high concentration precisely to the target ocular tissue, an approach that effectively limits systemic absorption. This localized delivery system contrasts significantly with orally administered NSAIDs.

General Purpose: Relief of Inflammation and Discomfort

The general purpose of the Flurbiprofen contained in Flurofen is to achieve a focused anti-inflammatory and analgesic effect. This function is accomplished by interfering with the synthesis of prostaglandins, which are key chemical messengers responsible for initiating pain and inflammation. Clinical research confirms that, due to its inhibitory action on the cyclooxygenase enzyme, the substance is reliably used to control and reduce inflammatory signs such as swelling and irritation. By suppressing the production of these inflammatory compounds, the drug helps to dampen the associated discomfort and visible effects of local inflammation.

Regulatory References

  1. Flurbiprofen Mechanism of Action (MedlinePlus)

What side effects are possible with Flurofen?

The safety profile of Flurofen (Flurbiprofen Ophthalmic Solution) is predominantly defined by effects localized to the eye, reflecting its topical application as a non-steroidal anti-inflammatory drug (NSAID).

Adverse Reaction Scope

Category Regulatory Statement
Key adverse reaction categories Primarily ocular disorders, including irritation, changes in pupil size (miosis or mydriasis), and ocular hyperemia (redness).
Frequency classification Many minor effects are of Incidence Not Known; however, some documents classify Eye Irritation, Eye Pain, and Hyphema (bleeding in the eye) as Common or Very Common in clinical use.
System-organ classes involved Eye disorders and Vascular Disorders (local manifestations of bleeding tendency).
Serious adverse reactions Potential for corneal complications (e.g., thinning, erosion, ulceration, perforation) associated with continued use, particularly in patients with pre-existing risk factors. Increased risk of ocular bleeding (hyphema) is documented, especially in the perioperative setting.
Population-specific safety Pregnancy (Third Trimester): The medication is contraindicated due to the NSAID class risk to the fetus. Pediatric Use: Safety and effectiveness have not been established in children.
Exposure-related patterns Transient burning and stinging is commonly reported upon instillation. Serious corneal effects are linked to continued or prolonged administration.

Safety-Related Restrictions

Use is restricted in individuals with known hypersensitivity to Flurbiprofen, aspirin, or other NSAIDs. Caution is also advised in patients with haemostatic defects or those receiving other medications that may prolong bleeding time. Furthermore, regulatory documents note that concurrent use with ophthalmic corticosteroids may enhance adverse effects and further delay healing.

Regulatory Safety Summary

The official regulatory safety information structures the risk profile by confirming that while minor local irritation is an expected, transient effect, the drug's properties as an NSAID carry specific, serious risks concerning corneal integrity and the tendency for ocular bleeding. This mandates explicit regulatory constraints regarding special populations and concurrent medication use.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information details the officially documented overdose profile for Flurofen (Flurbiprofen) based on government regulatory guidance and authoritative medical resources. This information is not intended as a substitute for professional medical advice.

Documented Overdose Manifestations

Symptoms of Flurofen overdose may range from mild to severe. Initial presentations often affect the central nervous and gastrointestinal systems, and may include lethargy, drowsiness, dizziness, nausea, vomiting, abdominal pain, and tinnitus (ringing in the ears).

Urgent Medical Attention Required

Immediate emergency medical attention must be sought for any suspected overdose or if severe systemic outcomes occur. Due to the lack of a specific pharmacological antidote, prompt supportive care is essential.

Immediate help is required for signs of severe complications, which include:

  • Gastrointestinal Bleeding: Bloody, black, or tarry stools; or vomiting blood/material resembling coffee grounds.
  • CNS Events: Seizures (convulsions), significant changes in consciousness, or coma.
  • Organ Dysfunction: Signs of acute renal failure or severe respiratory difficulty.

Management and Risks

Management of Flurofen overdose is primarily symptomatic and supportive, often requiring continuous monitoring of vital signs and renal function in a medical setting. Regulatory guidance notes that elderly patients and those with pre-existing organ impairment face an increased risk for serious and potentially fatal consequences from an NSAID overdose, such as major gastrointestinal or renal damage.

Therapeutic Uses of Flurofen

What Flurofen Treats: Main Uses and Benefits

Flurofen is a medication relevant for symptomatic support in situations where symptoms related to physical discomfort, inflammation, and systemic imbalance (such as fever) are key concerns. It is generally used across conditions presenting with acute episodes.

This medication is applied across domains where additional symptomatic support is needed, and may assist with symptoms associated with acute or episodic changes. It is commonly used to help with symptoms related to inflammatory or irritative states such as those associated with joints or muscles, and general conditions presenting with systemic or localized discomfort like those resulting from strains. The medication is considered relevant for symptoms that create noticeable physiological strain.

It is used for managing symptom clusters that interfere with daily functioning, such as stiffness and localized swelling. The general benefit contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Physical Discomfort, Inflammation, and Fever

Regulatory References

  1. DailyMed (NIH) Label Information

Eligibility and Restrictions for Use

This information is strictly based on official regulatory documents for Flurbiprofen (Flurofen).

Populations for Whom Use Is Contraindicated

Flurofen is contraindicated and must not be used by patients who fall into the following categories:

  • A known hypersensitivity or severe allergic reaction (such as asthma, hives, or anaphylaxis) to Flurbiprofen, aspirin, or any other NSAID (Nonsteroidal Anti-inflammatory Drug).
  • For treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
  • Individuals with active peptic ulceration/haemorrhage or a history of recurrent gastrointestinal (GI) bleeding.
  • Patients with severe heart failure, severe renal failure, or severe hepatic failure.
  • Pregnant women starting at 30 weeks gestation and later (third trimester).

Other Eligibility Restrictions

Age-Related Rules Condition-Specific Restrictions
Safety and effectiveness not established in children. Not recommended for those under 12 years of age. Avoid use in patients with advanced renal disease unless benefits clearly outweigh the risks of worsening kidney function.
Caution is required for older adults (65 years and over) due to increased risk of serious GI, renal, and cardiac adverse events. Avoid use in patients with severe heart failure due to the risk of fluid retention and edema.

What should I know about interactions with other medicines?

Flurofen Interactions with other medicines and products

Official regulatory information for Flurofen (Flurbiprofen ophthalmic solution) primarily documents interactions based on pharmacodynamic effects at the site of application and its general classification as a Non-Steroidal Anti-Inflammatory Drug (NSAID).


Interaction Scope and Restrictions

Property Description
Medicinal product categories with documented interactions: Topical Corticosteroids, Anticoagulants, Medicines that prolong bleeding time, Cholinergic Miotics.
Mechanistic basis of interactions: Pharmacodynamic: Interference with thrombocyte aggregation (anti-aggregating NSAID effect) and additive/opposing effects on ocular tissue.
Interaction-related restrictions: Co-administration is contraindicated in patients receiving medications that may prolong bleeding time (e.g., anticoagulants) due to the potential for increased ocular bleeding, particularly in conjunction with surgery.

Official Interaction Statements

  • The concomitant use of Topical Corticosteroids (steroid eye medicines) may increase the potential for delayed or slowed healing of ophthalmic tissue [FDA Prescribing Information].
  • Use is restricted in surgical patients with known bleeding tendencies or those receiving other medications that prolong bleeding time, such as warfarin or aspirin, to mitigate the risk of increased ocular bleeding [DailyMed (NIH)].
  • There are reports that the miotic effect of agents like Acetylcholine Chloride or Carbachol has been ineffective in some patients treated with Flurofen, although clinical and animal studies have not provided a definitive pharmacological basis for this opposition [FDA Prescribing Information].

This interaction structure emphasizes local ocular effects and surgical risks, with minimal official documentation of systemic pharmacokinetic drug interactions due to the solution's low systemic absorption.

Mechanism of Action

Molecular Inhibition of Cyclooxygenase (COX) Enzymes

The mechanism of Flurofen involves the localized modulation of specific biological signaling cascades within the ocular tissue. The active component, Flurbiprofen, acts as a non-selective, reversible inhibitor of the Cyclooxygenase (COX) enzyme system (specifically COX-1 and COX-2) that is present in the eye's tissues. By occupying the active site of these enzymes, Flurbiprofen initiates the cascade that suppresses the creation of Prostaglandin chemical mediators.


Disruption of Prostaglandin Synthesis and Function

This domain outlines the specific physiological pathway affected and the resulting change in smooth muscle tone. Inhibition of the COX enzyme prevents the conversion of Arachidonic Acid into Prostaglandins (PGs). These PGs are potent mediators of both tissue response and smooth muscle contraction. The resulting suppression of PG signaling alters the localized tissue response and is the specific physiological consequence that inhibits the prostaglandin-induced contraction (miosis) of the iris sphincter muscle.

Dosage and Administration Information

Official Instructions for Using Flurofen

The correct use of Flurofen, an active ingredient (Flurbiprofen) available in various formulations, is governed by the specific guidelines found in official prescribing information and product documentation.


Dosing and Administration

Dosage Form Route Standard Adult Dosing Frequency and Timing
Oral Tablet (e.g., 50 mg, 100 mg) Oral 200 to 300 mg per day, in total. Divided into two, three, or four administrations daily.
Lozenge (e.g., 8.75 mg) Oromucosal One lozenge per dose. Every 3 to 6 hours as required; maximum of 5 lozenges in 24 hours.

Procedural and Contextual Instructions

1. Administration Conditions:

  • Oral Tablets: Should be taken with or immediately after food to minimize the potential for gastrointestinal irritation.
  • Lozenges: Must be slowly sucked/dissolved in the mouth and moved around inside the mouth while sucking to avoid local mucosal irritation.

2. Duration of Use:

  • The lowest effective dosage should be used for the shortest duration necessary to achieve the individual patient's treatment goals.
  • For lozenges, use should typically be limited to a maximum of three days.

3. Population-Specific Rules:

  • Pediatric Use: Oral tablets are generally not recommended for use in children under 12 years of age. Lozenges are indicated for adolescents over 12 years.
  • Organ Impairment: Dosing adjustments may be required for patients with hepatic or renal impairment. Use is generally not recommended or contraindicated in cases of severe impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Flurofen

Evidence for Use in Stabilizing the Pupil During Eye Surgery

Research examined the ophthalmic solution in studies focused on conditions associated with acute or disruptive episodes, specifically during eye procedures like cataract surgery. These studies, typically Randomized Controlled Trials (RCTs) and controlled clinical trials, were used in research exploring how the solution was evaluated for pupil dynamics. The goal was to monitor outcomes related to the maintenance of pupil size during the hours immediately surrounding the operation.

Research examined measurements of pupil diameter during the surgery itself, focusing on the inhibition of pupil constriction (miosis). Long-term effects on the eye's internal dynamics following the procedure were not the focus of this research, meaning those outcomes are not fully established.

Evidence for Use in Managing Inflammation After Eye Surgery

Research explored the solution in studies examining outcomes related to post-surgical inflammation and discomfort using short-term RCTs and systematic reviews. Studies monitored outcomes related to physical discomfort and other signs of inflammation in the front part of the eye.

Research describes changes measured during the study period, with trials reporting measurements of differences in inflammatory signs over defined time intervals, often up to two weeks post-surgery. Furthermore, studies explored outcomes reflecting the incidence of complications, such as a specific type of swelling (cystoid macular edema). Findings contribute to understanding how outcomes were measured against a non-medicated control solution, and comparative data were collected against other agents.

Research Gaps and Areas of Scientific Uncertainty

Data are still emerging regarding the questions surrounding use beyond the short-term, and long-term effects are not fully established by the existing evidence. Studies included geriatric patients alongside other adults undergoing surgery. However, evidence is limited regarding the use of Flurofen ophthalmic solution in the pediatric population (children). The evidence does not currently support conclusions regarding use in this younger group without further dedicated research.

Frequently Asked Questions (FAQ)

Common questions about Flurofen (FAQ)


Q: How quickly does Flurofen usually start working?

Studies and official product information for the ophthalmic solution indicate a specific time frame is necessary for the drug’s action. When used before eye surgery, the solution is administered in doses starting 2 hours prior to the procedure. This timing reflects the period evaluated in research to monitor the drug’s intended effect.


Q: Can Flurofen cause changes in mood or sleep?

Regulatory documents for the systemic (oral) form of flurbiprofen describe potential central nervous system effects, including nervousness, anxiety, insomnia, depression, and somnolence. While the ophthalmic solution (eye drops) has very low systemic absorption, these types of effects are documented for the drug’s chemical class.


Q: How long does Flurofen stay in your system?

The elimination half-life for flurbiprofen, the active ingredient, is described in pharmacokinetic studies as approximately 5.7 hours for the systemic form. Since the ophthalmic solution is applied topically to the eye, systemic absorption is very low, but the half-life provides a reference for how quickly the substance is typically cleared from the body.


Q: Is Flurofen a controlled substance?

According to official regulatory classifications, Flurofen (Flurbiprofen) is categorized as a Non-Steroidal Anti-Inflammatory Drug (NSAID). It is not designated as a controlled substance under US regulation.


Q: What is the experience like for most people taking Flurofen?

The most commonly reported effects immediately after applying the ophthalmic solution are a temporary burning or stinging sensation in the eye. Official regulatory information also lists other common ocular reactions, such as general eye irritation and redness.


Q: Are there specific times of day to take Flurofen?

The official administration instructions relate the timing to the specific purpose of use. For example, for surgery, the ophthalmic solution is given at specific intervals leading up to the procedure. Oral forms are typically described as being divided for administration throughout the day, and official documents note that they are taken with or immediately after food.


Q: Can I have coffee or caffeine while taking Flurofen?

Official regulatory documents and product information for Flurofen (Flurbiprofen ophthalmic solution) do not list coffee or caffeine as a documented drug or food interaction.


Q: What should I do if I forget to use Flurofen?

Regulatory patient information generally describes applying it as soon as it is remembered. However, if it is almost time for the next scheduled dose, the official guidance is to skip the missed dose and continue with the regular schedule, to avoid using an excess amount.


Q: Does Flurofen affect my ability to drive or operate machinery?

Since the medication is applied directly to the eye, it may cause transient blurred or hazy vision temporarily following application. Because of this potential effect, patients are advised in official documents to wait until their vision clears before engaging in activities like driving or operating machinery.


Q: What should I tell a new doctor about my Flurofen use?

Regulatory documents describe certain existing conditions and concurrent medication use that a patient should discuss with their doctor. This includes any known allergies to Flurbiprofen, aspirin, or other NSAIDs, as well as any bleeding disorders or the use of other medications that may prolong bleeding time, such as blood thinners or topical corticosteroids.


Q: What if I have an allergic reaction to Flurofen?

The official FDA label notes that severe allergic reactions, such as anaphylaxis, are possible with the drug class. Regulatory patient counseling describes seeking emergency medical attention immediately if signs of a severe reaction are experienced, such as hives, difficulty breathing, or swelling of the face, lips, tongue, or throat.


Q: Does Flurofen change the way my immune system works?

Flurofen's mechanism of action involves inhibiting the Cyclooxygenase (COX) enzyme system, which suppresses the production of Prostaglandins. Prostaglandins are key chemical mediators of inflammation, which is an important process within the body’s broader immune response.


Q: What happens if I take more Flurofen than described?

Overdose following topical ophthalmic application is generally not anticipated to cause acute systemic toxicity. If the product is accidentally ingested, regulatory documents state that treatment should be symptomatic and supportive.


Q: Are there any restrictions on activity while using Flurofen?

Regulatory warnings primarily focus on the potential for increased ocular bleeding risk in surgical patients, which may impose certain post-operative restrictions. However, official product labels do not contain specific restrictions on general physical activities like routine exercise or swimming.


Q: Can Flurofen be crushed or split if it's hard to swallow?

The ophthalmic solution is an eye drop and should not be swallowed. For oral tablets, official administration instructions advise that they should be taken with or immediately after food, but regulatory documents do not provide guidance or instruction on crushing or splitting the tablets.


Q: What is the purpose of the different strengths of Flurofen?

Flurofen is available in different strengths and forms, such as 50 mg and 100 mg tablets, 8.75 mg lozenges, and the 0.03% ophthalmic solution. Official documents indicate that the specific dosage and strength are selected to match the intended treatment goal, such as pain relief, inflammation control, or pupil stabilization during surgery.

How should Flurofen be stored and disposed of?

How to Store and Dispose of Flurofen (Flurbiprofen Ophthalmic Solution)

Official Storage Requirements

Flurbiprofen ophthalmic solution must be stored at controlled room temperature, maintaining a range typically between 15°C to 25°C (59°F to 77°F). The product must be kept from freezing and protected from excessive heat, light, and moisture. Store the medication in its tightly closed original container to preserve sterility and integrity.

Child Safety and Stability

Keep the medicine out of the sight and reach of children. For some preparations, the solution should be discarded within one month after opening the container.

Disposal Instructions

Unused or expired Flurbiprofen ophthalmic solution should not be flushed down the toilet or poured down a sink. The preferred method for disposal is using a medicine take-back program. If a take-back option is unavailable, the product should be mixed with an unappealing substance, sealed in a bag, and placed in the household trash, following official guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Flurofen found in:

A-Z Index: